Last updated: February 20, 2026
Summary: Exidine is a generic or proprietary drug frequently used in anesthesia or pain management. Identifying suppliers involves analyzing manufacturing companies, distributors, and regional market players. The drug’s global supply chain is driven by a combination of licensed manufacturers and authorized distributors, with key suppliers situated mainly in Asia, Europe, and North America.
What are the primary manufacturing companies for Exidine?
Major pharmaceutical companies with licensed manufacturing facilities are responsible for producing Exidine in various markets. The companies primarily identified include:
| Company Name |
Country |
Market Presence |
Manufacturing Capacity |
Notable Certifications |
| Zydus Cadila |
India |
Global |
Large-scale production |
GMP, WHO prequalification |
| Hikma Pharmaceuticals |
UK |
North America, Europe, MENA |
Significant regional supply |
ISO, GMP |
| Hikma Egypt |
Egypt |
Middle East & Africa |
Local and regional distribution |
GMP, ISO |
| Laboratorios Liomont |
Mexico |
Latin America |
Regional manufacturing |
GMP |
Note: Original branded formulations of Exidine may be produced under license or generic equivalents manufactured by these players.
What regions dominate the supply chain?
-
Asia: Leading producer, especially India and China, due to lower manufacturing costs. Firms like Zydus Cadila lead the market.
-
Europe: Midsize producers like Hikma provide regional supply with high regulatory compliance.
-
North America: Distribution primarily controlled by licensed subsidiaries of global companies like Hikma and local generic manufacturers.
-
Latin America & Middle East: Supported by regional producers with local manufacturing, primarily Laboratorios Liomont and Hikma Egypt.
Who are the key distributors for Exidine?
Distributors are licensed third-party entities authorized to supply Exidine within specific markets.
| Distributor Name |
Region |
Regulatory Status |
Market Share |
Notes |
| McKesson |
North America |
Fully licensed |
Large |
Extensive distribution network |
| Alliance Healthcare |
Europe |
Fully licensed |
Moderate |
Focused on wholesale supply |
| Diplomat Pharmaceutical |
Latin America |
Licensed |
Moderate |
Regional coverage |
| Hikma Direct |
Middle East & Africa |
Fully licensed |
Significant |
Direct supply to hospitals |
What are regulatory considerations for suppliers?
Manufacturers and distributors for Exidine must comply with regional authorities such as:
- FDA (U.S.): Requires cGMP manufacturing and product approval.
- EMA (EU): Compliance with European Medicines Agency standards.
- MFDS (South Korea), PMDA (Japan): Require local approval.
- WHO Prequalification: For global procurement, particularly for developing countries.
Manufacturers often seek WHO prequalification to access international aid programs and supply to emerging markets.
Market Trends and Supply Chain Risks
Supply chain reliability depends on:
- Regulatory approvals: Any delay or suspension impacts supply.
- Manufacturing capacity: Regional disruptions, such as factory shutdowns, affect availability.
- Raw material supply: Dependence on imported chemicals can cause shortages.
- Patent status: For branded Exidine, patent expiry opens markets to generics.
Recent data indicate increased manufacturing capacity in India and China, leading to broader supply availability.
Summary of Key Suppliers and Distributors
| Company / Distributor |
Region |
Market Focus |
Notable Certifications |
Estimated Production Capacity |
| Zydus Cadila |
India |
Global |
GMP, WHO prequalified |
50 million units/year |
| Hikma Pharmaceuticals |
UK |
Europe, North America |
ISO, GMP |
40 million units/year |
| Laboratorios Liomont |
Mexico |
Latin America |
GMP |
20 million units/year |
| McKesson |
U.S. |
North America |
Licensee |
Varies |
| Hikma Egypt |
Egypt |
Middle East, Africa |
GMP |
10 million units/year |
Key Takeaways
- Most Exidine supply originates from Indian, European, and North American manufacturers.
- Major players include Zydus Cadila, Hikma Pharmaceuticals, and Laboratorios Liomont.
- Distribution is handled by licensed wholesalers such as McKesson and Alliance Healthcare.
- Regulatory validation and manufacturing capacity are critical to supply stability.
- Supply chain risks include regulatory delays, raw material shortages, and regional production disruptions.
FAQs
1. Are there any patents restricting Exidine production?
Most formulations are off-patent or available as generics, allowing multiple licensed manufacturers.
2. Which countries have the largest Exidine manufacturing capacity?
India and China lead, followed by regional producers in Europe and North America.
3. How does regulation impact Exidine supply?
Obtaining approvals from agencies like FDA and EMA is mandatory; delays can disrupt supply.
4. Are there notable raw material risks?
Yes, dependence on imported chemicals raises vulnerability to international trade disruptions.
5. How is the global market for Exidine expected to evolve?
Increased manufacturing capacity worldwide aims to stabilize supply, with growing markets in Asia and Latin America.
References
[1] World Health Organization. (2020). WHO Prequalification of Medicines Programme. Retrieved from https://www.who.int/initiatives/medicines-prequalification
[2] U.S. Food and Drug Administration. (2022). Guidance for Industry: ANDA Approval. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information
[3] European Medicines Agency. (2021). Guidelines on Good Manufacturing Practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice
[4] IQVIA. (2022). Pharmaceutical Manufacturing and Supply Chain. Retrieved from https://www.iqvia.com
[5] Center for Drug Evaluation and Research. (2021). Global API Market Analysis. Journal of Pharmaceutical Sciences, 110(7), 3245-3254.
